Akebia Therapeutics (AKBA) Interest & Investment Income (2014 - 2019)
Akebia Therapeutics' (AKBA) quarterly Interest & Investment Income came in at -$6000.0 in Q4 2019, down 104.05% year-on-year from $148000.0 in Q4 2018, and up 64.71% on a QoQ basis from -$17000.0 in Q3 2019.
Akebia Therapeutics (AKBA) Interest & Investment Income (2014 - 2019) Analysis & Trends
Akebia Therapeutics (AKBA) has 6 years of Interest & Investment Income data on file, last reported at -$6000.0 in Q4 2019.
- On a quarterly basis, Interest & Investment Income fell 104.05% year-over-year to -$6000.0 in Q4 2019; TTM through Dec 2019 was $261000.0, a 44.2% increase from a year earlier, with the FY2019 full-year figure at $261000.0, up 44.2% from the prior year.
- Interest & Investment Income for Q4 2019 stood at -$6000.0, up from -$17000.0 in the prior quarter.
- Over the last five years, Interest & Investment Income for AKBA reached as high as $225000.0 in Q1 2019 and fell as low as -$764000.0 in Q4 2016.
- Historically, Interest & Investment Income has averaged -$59250.0 across 5 years, with a median of -$7000.0 in 2015.
- Across the five-year window, Interest & Investment Income surged 1550.0% in 2015 and plunged 588.46% in 2017, its largest moves.
- Year by year, Interest & Investment Income stood at -$584000.0 in 2015, then plunged by 30.82% to -$764000.0 in 2016, then surged by 71.34% to -$219000.0 in 2017, then surged by 167.58% to $148000.0 in 2018, then tumbled by 104.05% to -$6000.0 in 2019.
- Per Business Quant data, the three most recent Interest & Investment Income figures were -$6000.0 in Q4 2019, -$17000.0 in Q3 2019, and $59000.0 in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 32.85 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 41.80 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 28.10 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Akebia Therapeutics | 339.15 Mn | 176.55 Mn | 41.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | -6,000.00 |
| Sep 30, 2019 | -17,000.00 |
| Jun 30, 2019 | 59,000.00 |
| Mar 31, 2019 | 225,000.00 |
| Dec 31, 2018 | 148,000.00 |
| Sep 30, 2018 | 50,000.00 |
| Jun 30, 2018 | 91,000.00 |
| Mar 31, 2018 | -108,000.00 |
| Dec 31, 2017 | -219,000.00 |
| Sep 30, 2017 | 73,000.00 |
| Jun 30, 2017 | -75,000.00 |
| Mar 31, 2017 | -179,000.00 |
| Dec 31, 2016 | -764,000.00 |
| Sep 30, 2016 | -44,000.00 |
| Jun 30, 2016 | 63,000.00 |
| Mar 31, 2016 | -26,000.00 |
| Dec 31, 2015 | -584,000.00 |
| Sep 30, 2015 | 20,000.00 |
| Jun 30, 2015 | 116,000.00 |
| Mar 31, 2015 | -8,000.00 |